fda approval semaglutide mash Receives for Treatment of Novo's Wegovy becomes first GLP-1

Some patients report light-headedness particularly during the initial weeks of treatment or following dose increases

The testing labs guide covers how to verify what you are actually receiving

Hypoglycemic episodes trigger catecholamine release, resulting in tachycardia and palpitations as part of the counter-regulatory response

However, this initial decrease comes mainly from fluid loss, appetite/eating changes, and potential GI side effects not necessarily fat loss

Single vs Quadruple Receptor Activation# Weight Loss Data# Critical caveat: Bioglutide achieved comparable weight loss to semaglutide in 13 weeks versus 68 weeks, which if sustained would represent dramatically superior efficacy

Further reading A guide to prescription weight loss treatments Wegovy interactions: what you need to know Reviewed by Dr